Allahabad HC: Codeine Syrup NDPS Diversion Triggers Full NDPS Act

• The Allahabad High Court ruled that codeine-based cough syrup diverted for intoxication falls under the NDPS Act, even if its codeine concentration is within permissible limits.
• Justice Arun Kumar Singh Deshwal stated that statutory exemptions for codeine preparations apply only when used for bona fide therapeutic purposes.
• Once diverted for substance abuse, such medicinal preparations are reclassified as 'manufactured drugs' under Section 2(xi) of the NDPS Act.
• The court cited the `Hira Singh vs Union of India` precedent, mandating that the entire weight of the syrup mixture be considered for NDPS Act violations. However, this precedent is currently under re-examination by the Supreme Court.
• This decision underscores that the intent of use, rather than just concentration, determines liability for `codeine cough syrup intoxication NDPS`.

The court's decision clarifies that the moment such medicinal products are diverted into illicit supply chains for substance abuse, they forfeit any legal immunity.

The Allahabad High Court has issued a significant ruling, asserting that the stringent provisions of the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985, are applicable to codeine-based cough syrup when it is possessed, transported, or sold for the purpose of intoxication. This holds true even if the concentration of codeine within the syrup falls within what are typically considered permissible limits.

In the case of `Bhola Prasad v. State of U.P.`, Justice Arun Kumar Singh Deshwal underscored that any statutory exemption granted to codeine preparations is strictly contingent upon their handling for legitimate therapeutic uses. The court's decision clarifies that the moment such medicinal products are diverted into illicit supply chains for substance abuse, they forfeit any legal immunity.

This interpretation means that the intent behind the possession or distribution of the syrup is paramount. If the product, despite being manufactured as a cough suppressant with a permitted quantity of codeine, is stocked, sold, or transported for non-medicinal purposes like intoxication, it will be treated as a `manufactured drug` under the NDPS Act.

The High Court's ruling hinges on the conditional nature of exemptions for codeine preparations. Specifically, the statutory immunity provided under Entry 35 of the Central Government Notification dated November 14, 1985, is explicitly tied to the product's use for bona fide therapeutic purposes. Once this condition is violated through diversion for illicit use, the preparation is reclassified under Section 2(xi) of the `Narcotic Drugs and Psychotropic Substances Act 1985`.

Furthermore, the court invoked the landmark Supreme Court precedent established in `Hira Singh vs Union of India` to determine the quantity of the illicit substance. This precedent dictates that in cases involving the illicit trafficking of narcotic mixtures, the weight of the entire formulation, not just the pure drug content, must be considered. However, the Supreme Court has recently agreed to re-examine this judgment. Consequently, for `codeine cough syrup intoxication NDPS` cases, the entire mixture of syrup will be treated as codeine for the purpose of applying the Act's penalties.

This judgment carries significant implications for pharmaceutical companies, distributors, and pharmacists involved in the handling of codeine-based cough syrups. It firmly establishes that the legal status of these products shifts from a regulated medicine to a `manufactured drug` under the NDPS Act the moment they are diverted from their intended medicinal use for intoxication.

The ruling emphasizes that adherence to concentration limits alone is insufficient to avoid liability under the NDPS Act if the product's ultimate purpose is illicit. The court's clear stance on `Allahabad HC codeine syrup NDPS diversion` highlights the need for stringent controls throughout the supply chain to prevent these products from being misused, reinforcing the principle that intent to intoxicate overrides permissible concentration levels.

Lawyers advising pharmaceutical companies, distributors, or pharmacists must ensure strict controls and due diligence to prevent diversion of codeine-based cough syrups, as this ruling clarifies that even permissible concentrations attract stringent NDPS Act liability if the product is intended for intoxication. Defense lawyers should note the court's emphasis on the purpose of use over concentration limits and the application of the Hira Singh precedent for entire mixture weight.

Source: Original reporting via Live Law